Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension

References

• Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090.
   PubMed Web of Science ®Google Scholar
• Kalouda P, Keskini C, Anastasopoulos E, et al. Achievements and limits of current medical therapy of glaucoma. Dev Ophthalmol. 2017;59:1–14.
   PubMedGoogle Scholar
• Gordon MO, Beiser JA, Brandt JD, et al. The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):714–720. discussion 829-730.
   PubMedGoogle Scholar
• Schulzer M. Intraocular pressure reduction in normal-tension glaucoma patients. The Normal Tension Glaucoma Study Group. Ophthalmology. 1992;99(9):1468–1470.
   PubMed Web of Science ®Google Scholar
• Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International dorzolamide study group. Arch Ophthalmol. 1995;113(8):1009–1016.
   PubMed Web of Science ®Google Scholar
• Olthoff CM, Schouten JS, van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112(6):953–961.
   PubMed Web of Science ®Google Scholar
• Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence. 2011;5:441–463.
   PubMed Web of Science ®Google Scholar
• Tanna AP, Johnson M. Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension. Ophthalmology. 2018;125(11):1741–1756.
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmol. 2015;93(4):e254–260.
   PubMed Web of Science ®Google Scholar
• Bacharach J, Dubiner HB, Levy B, et al. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology. 2015;122(2):302–307.
   PubMed Web of Science ®Google Scholar
• Addis VM, Miller-Ellis E. Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy. Clin Ophthalmol. 2018;12:2649–2657.
   PubMed Web of Science ®Google Scholar
• Moshirfar M, Parker L, Birdsong OC, et al. Use of Rho kinase inhibitors in ophthalmology: a review of the literature. Med Hypothesis Discov Innov Ophthalmol. 2018;7(3):101–111.
   PubMedGoogle Scholar
• Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. Ophthalmology. 2016;123(1):129–140.
   PubMed Web of Science ®Google Scholar
• Katz LJ, Steinmann WC, Kabir A, et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. J Glaucoma. 2012;21(7):460–468.
   PubMed Web of Science ®Google Scholar
• Lin CW, Sherman B, Moore LA, et al. Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma. J Ocul Pharmacol Ther. 2018;34(1–2):40–51.
   PubMed Web of Science ®Google Scholar
• Aerie Pharmaceuticals Inc. ROCKLATAN™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, for topical ophthalmic solution. Highlights of prescribing information, FDA. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208259s000lbl.pdf
   Google Scholar
• Ren R, Li G, Le TD, et al. Netarsudil increases outflow facility in human eyes through multiple mechanisms. Invest Ophthalmol Vis Sci. 2016;57(14):6197–6209.
   PubMed Web of Science ®Google Scholar
• Grisk O. Potential benefits of rho-kinase inhibition in arterial hypertension. Curr Hypertens Rep. 2013;15(5):506–513.
   PubMed Web of Science ®Google Scholar
• Levy B, Ramirez N, Novack GD, et al. Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers. Am J Ophthalmol. 2015;159(5):980–985 e981.
   PubMed Web of Science ®Google Scholar
• Sjoquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47(Suppl 1):S6–12.
   PubMed Web of Science ®Google Scholar
• Alm A. Latanoprost in the treatment of glaucoma. Clin Ophthalmol. 2014;8:1967–1985.
   PubMedGoogle Scholar
• Sturdivant JM, Royalty SM, Lin CW, et al. Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma. Bioorg Med Chem Lett. 2016;26(10):2475–2480.
   PubMed Web of Science ®Google Scholar
• Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs. 2007;21(3):167–177.
   PubMed Web of Science ®Google Scholar
• Rao PV, Pattabiraman PP, Kopczynski C. Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: bench to bedside research. Exp Eye Res. 2017;158:23–32.
   PubMed Web of Science ®Google Scholar
• Kiel JW, Kopczynski CC. Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits. J Ocul Pharmacol Ther. 2015;31(3):146–151.
   PubMed Web of Science ®Google Scholar
• Wang RF, Williamson JE, Kopczynski C, et al. Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015;24(1):51–54.
   PubMed Web of Science ®Google Scholar
• Li G, Mukherjee D, Navarro I, et al. Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes. Eur J Pharmacol. 2016;787:20–31.
   PubMed Web of Science ®Google Scholar
• Somlyo AP. Signal transduction. Rhomantic interludes raise blood pressure. Nature. 1997;389(6654): 908–909. 911.
   PubMed Web of Science ®Google Scholar
• Shaw PX, Sang A, Wang Y, et al. Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury. Exp Eye Res. 2017;158:33–42.
   PubMed Web of Science ®Google Scholar
• Lim KS, Nau CB, O’Byrne MM, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008;115(5):790–795.e794.
   PubMed Web of Science ®Google Scholar
• Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998;67(2):179–191.
   PubMed Web of Science ®Google Scholar
• Sagara T, Gaton DD, Lindsey JD, et al. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol. 1999;117(6):794–801.
   PubMedGoogle Scholar
• Weinreb RN, Kashiwagi K, Kashiwagi F, et al. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997;38(13):2772–2780.
   PubMed Web of Science ®Google Scholar
• Lindsey JD, Kashiwagi K, Kashiwagi F, et al. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci. 1997;38(11):2214–2223.
   PubMed Web of Science ®Google Scholar
• Kim JW, Lindsey JD, Wang N, et al. Increased human scleral permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci. 2001;42(7):1514–1521.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Lindsey JD, Marchenko G, et al. Prostaglandin FP agonists alter metalloproteinase gene expression in sclera. Invest Ophthalmol Vis Sci. 2004;45(12):4368–4377.
   PubMed Web of Science ®Google Scholar
• Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008;53(Suppl1):S107–120.
   PubMed Web of Science ®Google Scholar
• Poyer JF, Millar C, Kaufman PL. Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci. 1995;36(12):2461–2465.
   PubMed Web of Science ®Google Scholar
• Kamphuis W, Schneemann A, van Beek LM, et al. Prostanoid receptor gene expression profile in human trabecular meshwork: a quantitative real-time PCR approach. Invest Ophthalmol Vis Sci. 2001;42(13):3209–3215.
   PubMed Web of Science ®Google Scholar
• Digiuni M, Fogagnolo P, Rossetti L. A review of the use of latanoprost for glaucoma since its launch. Expert Opin Pharmacother. 2012;13(5):723–745.
   PubMedGoogle Scholar
• Lewis RA, Levy B, Ramirez N, et al. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol. 2016;100(3):339–344.
   PubMed Web of Science ®Google Scholar
• Asrani S, Robin AL, Serle JB, et al. Netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure: 3-Month data from a randomized phase 3 trial. Am J Ophthalmol. 2019;207:248–257.
   PubMed Web of Science ®Google Scholar
• Walters TR, Ahmed IIK, Lewis RA, et al. Once-daily netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure in the randomized phase 3 MERCURY-2 study. Ophthalmol Glaucoma. 2019;2:280–289.
   Google Scholar
• Netland P. Glaucoma medical therapy: principles and management. 2 ed. New York: Oxford University Press; 2008. p. 33–155.
   Google Scholar
• Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian latanoprost study group. Ophthalmology. 1995;102(12):1743–1752.
   PubMed Web of Science ®Google Scholar
• Fristrom B. A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension. Acta Ophthalmol Scand. 1996;74(2):140–144.
   PubMedGoogle Scholar
• Thomas R, Parikh R, Sood D, et al. Efficacy and safety of latanoprost for glaucoma treatment: a three-month multicentric study in India. Indian J Ophthalmol. 2005;53(1):23–30.
   PubMedGoogle Scholar
• Manufacturer’s information. Xalatan®latanoprost ophthalmic solution. Puurs: Pfizer; 2009 January.
   Google Scholar
• De Santis M, Lucchese A, Carducci B, et al. Latanoprost exposure in pregnancy. Am J Ophthalmol. 2004;138(2):305–306.
   PubMed Web of Science ®Google Scholar
• Fiscella G, Jensen MK. Precautions in use and handling of travoprost. Am J Health Syst Pharm. 2003;60: 484–485. author reply 485.
   PubMedGoogle Scholar
• Coppens G, Stalmans I, Zeyen T. Glaucoma medication during pregnancy and nursing. Bull Soc Belge Ophtalmol. 2010;(314):33–36.
   PubMedGoogle Scholar
• Johnson SM, Martinez M, Freedman S. Management of glaucoma in pregnancy and lactation. Surv Ophthalmol. 2001;45(5):449–454.
   PubMed Web of Science ®Google Scholar
• Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18(5):205–215.
   PubMed Web of Science ®Google Scholar
• Schuman JS. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine study groups 1 and 2. Ophthalmology. 2000;107(6):1171–1177.
   PubMed Web of Science ®Google Scholar
• Rahmatnejad K, Pruzan NL, Amanullah S, et al. Surgical Outcomes of Gonioscopy-assisted Transluminal Trabeculotomy (GATT) in patients with open-angle glaucoma. J Glaucoma. 2017;26(12):1137–1143.
   PubMed Web of Science ®Google Scholar
• Garg A, Vickerstaff V, Nathwani N, et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology. 2019;126:1238–1248.
   Web of Science ®Google Scholar